Sushrut Waikar, MD
Norman G. Levinsky Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Dept of Medicine
Nephrology

MD, Yale University
MPH, Harvard School of Public Health



Sushrut S. Waikar, MD, MPH received a BA in English and Neuroscience at Amherst College, his MD at Yale, and an MPH at Harvard. He is the Norman G. Levinsky Professor of Medicine at Chobanian and Avedisian School of Medicine and Chief of Nephrology at Boston Medical Center. Dr. Waikar's research interests and active projects include epidemiologic, translational, and interventional studies to address novel and clinically important questions in nephrology. Current areas of investigation include optimal diagnostic testing in acute kidney injury and chronic kidney disease; biomarkers of kidney pathology and kidney fibrosis; the identification of relevant targets for interventional trials in kidney disease; and randomized controlled trials. He is a Principal Investigator of several NIH grants including the Kidney Precision Medicine Project (U01 DK133092), Multi-omics and Chronic Kidney Disease: Correlation with Histology (R01 DK108803), Discovery Science Collaborative for CKDu (U01 DK130060), NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial (U01AG076789) andThe Boston University Kidney and Medical Engineering Program (BU-KIDMEP, R25 DK128858).

Diversity, Equity, Inclusion and Accessibility

Diversity is a defining and fundamental feature of our biology and society. Diversity allowed for evolution and is a prerequisite for our continued growth as a people. My first memories and experiences with diversity came as a four-year-old immigrant to Chicago, IL by way of a relatively homogenous city in central India. Diversity for me began with an intense feeling of otherness: I had black, white, and brown classmates, but I "belonged" to none of them because of my accented and under-developed English. Growing up in a predominantly white and middle-class neighborhood in suburban Chicago, I struggled to feel comfortable in my own skin, which stood out starkly in class pictures. While my experiences as an immigrant are not unique and were in fact privileged compared to so many, they shaped my appreciation and empathy for others who, like me, don't feel like they quite "belong."

As a resident in internal medicine, I had the great fortune of being assigned to a primary care clinic at San Francisco General Hospital, where virtually none of my patients hailed from the "majority," whether in terms of skin color, income, or freedom from addiction. Later, as a trainee in nephrology, I was exposed to the stark disparities in kidney diseases across so many of these same strata. Now as a member and leader at Boston Medical Center, the institution that proudly serves as the region's safety net hospital, I hope to be able to use my position to advance diversity, equity, inclusion, and accessibility across our institution. My activities in pursuit of social justice and DEIA include the following:

- Commitment to highlighting historical instances of subtle racism in nephrology: for over 20 years, kidney function was estimated differently for black vs. non-black individuals through an equation that initially began as a biostatistical/epidemiological adjustment for "best fit." Over the years, it slowly and belatedly dawned on many in our field that singling out black vs. non-black people while estimating organ function perpetuated a racialized view of humanity. My contributions to this discussion in nephrology include 1) co-authorship on a manuscript on race, genetic ancestry, and kidney function estimation (Hsu et al., New Engl J Med 2021); 2) a perspectives piece entitled "Separate and Unequal: Race-Based Algorithms and Implications for Nephrology" (Schmidt and Waikar, J Am Soc Nephrol. 2021) which highlights other examples of subtle racism in our field; and 3) advocating for and helping to implement the race-neutral kidney function estimating equation at Boston Medical Center.

- Scientific activities on minoritized and marginalized populations: I am a Principal Investigator of the Kidney Precision Medicine Project, a study of the molecular underpinnings of common forms of kidney disease that disproportionately afflict minority populations in the United States. Boston Medical Center has been a major contributor to this effort and in particular on emphasiing the need for recruitment of diverse populations and expanding the scientific focus to social determinants of health. I am also a Principal Investigator of the Chronic Kidney Disease of Uncertain Etiology Consortium, a study of a mysterious kidney disease epidemic afflicting poor agricultural communities in Central America and India. Boston University has been a leader in this scientific investigation for many years, and as of 2021 Boston Medical Center along with co-PI's at Stanford and Beth Israel Deaconess Medical Center are leading the efforts as the Renal Science Core to understand the cause(s) of this condition.

Much work remains to be done in our institution. Areas of focus include:
- Increasing the diversitry of our nephrology faculty to better mirror the diversity of the patients we serve
- Recruiting and training a diverse group of fellows in nephrology at Boston Medical Center and nationally
- Community outreach to neighborhoods to enlist non-academic partners in the pursuit of kidney health

Section Chief
Boston University Chobanian & Avedisian School of Medicine
Medicine
Nephrology




Role of Amphiregulin in kidney fibrosis- DK121200
09/15/2019 - 08/31/2024 (PI)
Washington University National Institutes

Histopathology, outcomes, and biomarkers of advanced chronic
01/01/2022 - 12/31/2023 (PI)
Johnson and Johnson

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
08/20/2020 - 08/20/2023 (PI)
Vertex Pharmaceuticals

Electronic Tools to Increase Recognition and Improve Primary
09/16/2019 - 07/31/2023 (PI)
Brigham and Womens Hospital National Institute o
5R01DK116898-04

A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis
07/29/2020 - 07/29/2023 (PI)
Vertex Pharmaceuticals

The Boston University Kidney and Medical Engineering Program (BU-KIDMEP)
04/01/2021 - 02/28/2023 (PI)
National Institutes of Health/DHHS/NIH
1R25DK128858-01

Boston Kidney Biopsy Cohort - Master Agreement
01/03/2022 - 01/02/2023 (PI)
Natera, Inc.

ADVANCING MULTIPARAMETRIC KIDNEY FUNCTIONAL MRI TO PHENOTYPE INDIVIDUALS WITH CKD
07/01/2020 - 06/30/2022 (PI)
University of Washington, Seattle NIH-NIDDK
5U2CDK114886-04

Kidney Physiology Phenotyping in the Kidney Precision Medicine Project
07/01/2020 - 06/30/2022 (PI)
University of Washington, Seattle NIH-NIDDK

Harvard Chronic Kidney Disease Research Biopsy Center_Copy
09/01/2019 - 06/30/2022 (PI)
Brigham and Womens Hospital National Institute o
5UH3DK114915-05

Showing 10 of 19 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs
2022 Boston Chronic Kidney Disease Research Biopsy Center 1U01DK133092-01
2022 NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial 1U01AG076789-01
2022 Discovery Science Collaborative for CKDu 5U01DK130060-02
2022 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 5R25DK128858-02
2022 Multi-Omics and Chronic Kidney Disease: Correlation with Histology 2R01DK108803-06A1
2021 Discovery Science Collaborative for CKDu 1U01DK130060-01
2021 The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) 1R25DK128858-01
2021 Harvard Chronic Kidney Disease Research Biopsy Center 5UH3DK114915-05
2020 Metabolomics and Renal Functional Reserve 5R21DK119751-02
2020 Harvard Chronic Kidney Disease Research Biopsy Center 5UH3DK114915-04
Showing 10 of 47 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Perkovic V, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, DiMino TL, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Solomon S, Taft L, Wanner C, Waikar SS, Wheeler DC, Wiecek A, Singh AK. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 Oct 19; 37(11):2157-2170. PMID: 34865143
     
  2. Causland FRM, Ravi KS, Curtis KA, Kibbelaar ZA, Short SAP, Singh AT, Correa S, Waikar SS. A randomized controlled trial of two dialysate sodium concentrations in hospitalized hemodialysis patients. Nephrol Dial Transplant. 2022 Jun 23; 37(7):1340-1347. PMID: 34792161; PMCID: PMC9217525; DOI: 10.1093/ndt/gfab329;
     
  3. Limonte CP, Valo E, Drel V, Natarajan L, Darshi M, Forsblom C, Henderson CM, Hoofnagle AN, Ju W, Kretzler M, Montemayor D, Nair V, Nelson RG, O'Toole JF, Toto RD, Rosas SE, Ruzinski J, Sandholm N, Schmidt IM, Vaisar T, Waikar SS, Zhang J, Rossing P, Ahluwalia TS, Groop PH, Pennathur S, Snell-Bergeon JK, Costacou T, Orchard TJ, Sharma K, de Boer IH. Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes. Diabetes Care. 2022 Jun 02; 45(6):1416-1427.View Related Profiles. PMID: 35377940; PMCID: PMC9210873; DOI: 10.2337/dc21-2204;
     
  4. Correa S, Guerra-Torres XE, Ravi KS, Mothi SS, Waikar SS, Mc Causland FR. Risk of Intradialytic Hypotension by Day of the Week in Maintenance Hemodialysis. ASAIO J. 2022 Jun 01; 68(6):865-873. PMID: 34494985
     
  5. Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 Jun 01; 182(6):592-602. PMID: 35377393; PMCID: PMC8981070; DOI: 10.1001/jamainternmed.2022.0605;
     
  6. Samal L, D'Amore JD, Gannon MP, Kilgallon JL, Charles JP, Mann DM, Siegel LC, Burdge K, Shaykevich S, Lipsitz S, Waikar SS, Bates DW, Wright A. Impact of Kidney Failure Risk Prediction Clinical Decision Support on Monitoring and Referral in Primary Care Management of CKD: A Randomized Pragmatic Clinical Trial. Kidney Med. 2022 Jul; 4(7):100493. PMID: 35866010; PMCID: PMC9293940; DOI: 10.1016/j.xkme.2022.100493;
     
  7. Singh AK, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Perkovic V, Solomon S, Wanner C, Waikar SS, Wheeler DC, Wiecek A. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 Apr 25; 37(5):960-972. PMID: 33744933; PMCID: PMC9035347; DOI: 10.1093/ndt/gfab065;
     
  8. Eneanya ND, Lakin JR, Paasche-Orlow MK, Lindvall C, Moseley ET, Henault L, Hanchate AD, Mandel EI, Wong SPY, Zupanc SN, Davis AD, El-Jawahri A, Quintiliani LM, Chang Y, Waikar SS, Bansal AD, Schell JO, Lundquist AL, Tamura MK, Yu MK, Unruh ML, Argyropoulos C, Germain MJ, Volandes A. Video Images about Decisions for Ethical Outcomes in Kidney Disease (VIDEO-KD): the study protocol for a multi-centre randomised controlled trial. BMJ Open. 2022 Apr 08; 12(4):e059313.View Related Profiles. PMID: 35396311; PMCID: PMC8996022; DOI: 10.1136/bmjopen-2021-059313;
     
  9. Amatruda JG, Katz R, Sarnak MJ, Gutierrez OM, Greenberg JH, Cushman M, Waikar S, Parikh CR, Schelling JR, Jogalekar MP, Bonventre JV, Vasan RS, Kimmel PL, Shlipak MG, Ix JH. Biomarkers of Kidney Tubule Disease and Risk of End-Stage Kidney Disease in Persons With Diabetes and CKD. Kidney Int Rep. 2022 Jul; 7(7):1514-1523. PMID: 35812302; PMCID: PMC9263389; DOI: 10.1016/j.ekir.2022.03.033;
     
  10. Sarnak MJ, Katz R, Ix JH, Kimmel PL, Bonventre JV, Schelling J, Cushman M, Vasan RS, Waikar SS, Greenberg JH, Parikh CR, Coca SG, Sabbisetti V, Jogalekar MP, Rebholz C, Zheng Z, Gutierrez OM, Shlipak MG. Plasma Biomarkers as Risk Factors for Incident CKD. Kidney Int Rep. 2022 Jul; 7(7):1493-1501. PMID: 35812266; PMCID: PMC9263237; DOI: 10.1016/j.ekir.2022.03.018;
     
Showing 10 of 245 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 245 publications over 18 distinct years, with a maximum of 41 publications in 2021

YearPublications
20051
20064
20073
20086
20096
20103
20119
201215
201315
201413
201512
201617
201715
201811
201923
202036
202141
202215
Contact for Mentoring:
Waikar's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department